EDUCATION

2009 - PhD in Molecular Biology, Faculty of Biology (FB), UB
(Polymorphisms in phenylalanine hydroxylase gene as gene expression regulators, phenotype modulators and population genetic markers)
2004 - B.Sc. in Molecular Biology, FB, University of Belgrade

RESEARCH EXPERIENCE

2020 - Full Research Professor, IMGGE, UB
2015 – 2020 - Senior Research Associate, IMGGE, UB
2010 - 2015 - Research Associate, IMGGE, UB
2007 - 2010 - Research Assistant, IMGGE, UB
2006 - 2007 - Research Trainee, IMGGE, UB

OTHER ACTIVITIES

Since 2020 - Development Management of the Sector for Laboratory Investigations at the IMGGE
Since 2020 - Professor at the postgraduate courses in Molecular biology at the Faculty of Biology, University of Belgrade: “Genes and human diseases”
2010-2020 - Teaching experience at two postgraduate courses in Molecular biology at the Faculty of Biology, University of Belgrade: “Molecular genetics in diagnostics, prevention and therapy of human diseases” and “Personalized Medicine and Pharmacogenetics”
Since 2019 - Secretary of the International Collaboration on Rare Diseases and Orphan Drugs (Since 2019) – www.icord.es
2014-2019 – Member of the Board of the International Collaboration on Rare Diseases and Orphan Drugs – www.icord.es
2016-2018 - Development Management of the Sector for Laboratory Investigations at the IMGGE
Since 2016 - Genomic Medicine Alliance Ambasador, http://www.genomicmedicinealliance.org
Since 2010 - Assistant Coordinator of Serbian ORPHANET team, www.orpha.net
Since 2010 - Member of Expert Committee of National Organization for Rare Diseases of Serbia, NORBS, www.norbs.rs

RESEARCH INTEREST

Dedicated to fundamental and applied biomedical research with a focus on rare diseases. Conducted pioneer studies on molecular-genetic basis of several rare diseases in Serbian population (phenylketonuria, tetrahydrobiopterin dificiencies, organic acidurias, thalassemia, congenital adrenal hyperplasia etc.), which enabled genetic diagnostics of these diseases in the country. Performs functional studies of novel genetic variants (transcriptional studies, protein activity studies) in order to understand the impact of the variant on the rare disease phenotype, to elucidate genotype-phenotype correlation and to assess genotype-base prediction of drug efficacy (e.g. responsiveness of phenylketonuria patients to drug KUVAN).